Abstract
Five hundred nineteen Streptococcus pneumoniae isolates from nasopharyngeal aspirates of 3,157 children (age, <16 years) participating in a respiratory surveillance study in Hong Kong in 2005 and 2006 indicated that 64.9% and 37.2% of the isolates were not susceptible to penicillin and cefotaxime, respectively. The rate of potential coverage by the seven-valent conjugate vaccine was 72.3%, and the rate increased to 74.6% for serogroup-specific types.
Penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) has evolved to be a global problem in recent decades. The introduction of a seven-valent (types 4, 6B, 9V, 14, 18C, 19F, and 23F) pneumococcal conjugate vaccine (PCV7) in the United States and Europe has demonstrated its impact in reducing invasive disease (1) and otitis media (4). Invasive disease caused by serotypes of PNSP clones have diminished significantly in the United States (15, 17). In addition, the rate of nasopharyngeal carriage of vaccine serotypes in children has declined, thus reducing the rates of transmission and the numbers of infections caused by these serotypes (16).
Pneumococci are “inhabitants” of the oral flora and colonize the nasopharynx, particularly in young children from birth, and the level of colonization gradually declines with age. Although their isolation from the nasopharynx of children with respiratory illnesses does not necessarily represent pneumococcal disease, nasopharyngeal colonization is often the first step in the development of pneumococcal infections. Coinfection or secondary bacterial infection may result from organisms that had colonized the nasopharynx. Invasive diseases with meningitis and bacteremia remain “tip-of-the-iceberg” presentations for pneumococcal disease, but S. pneumoniae is infrequently cultured from cerebrospinal fluid and blood, especially when antibiotics have been given. Besides, tympanic aspirate or sputum specimens are rarely obtained from children. We thus sought to examine the serotypes and antibiotic susceptibilities of S. pneumoniae strains isolated from nasopharyngeal aspirates (NPAs) obtained in a prospective surveillance study of childhood acute respiratory illness. As PCV7 has been made available in Hong Kong since August 2006, the serotypes and antibiotic susceptibilities of the S. pneumoniae isolates obtained in this study represent those that existed prior to the introduction of PCV7.
Pneumococcal isolates.
All children ages >1 month to 15 years who were hospitalized at the Prince of Wales Hospital (PWH) from March 2005 to March 2006 for a suspected respiratory or febrile illness and from whom an NPA was obtained were included in the study. PWH is a 1,350-bed teaching hospital that serves a population of approximately 1,000,000 in the New Territories East Region of Hong Kong. An NPA was obtained from each child and placed in 2 ml of transport medium containing Hanks' balanced salt solution, 5% bovine serum albumin, and 7.5% NaHCO3 without antibiotics; and 1 μl was cultured onto blood agar with or without gentamicin (5 mg/liter). The S. pneumoniae isolates were saved in 10% glycerol brain heart infusion broth at −70°C. Duplicate isolates from the same child during the same hospital admission were excluded.
Antibiotic susceptibility testing.
The MICs of penicillin G, cefotaxime, chloramphenicol, tetracycline, erythromycin, lincomycin, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and linezolid were determined by the broth microdilution method, as described by the Clinical Laboratory Standards Institute (3).
Capsular typing.
Capsular typing was performed with Pneumotest antisera (Statens Seruminstitut, Copenhagen, Denmark), according to the manufacturer's instruction. Isolates that were not typeable by the Pneumotest were classified as nontypeable. Typing of certain serogroups into serotypes was done by using a combination of factor sera and a multiplex PCR that targeted the serotypes of the seven-valent vaccine (13).
The rate of isolation of S. pneumoniae from the NPAs of 3,157 children ages 1 month to 15 years was 16.9%. A total of 519 nonduplicate S. pneumoniae isolates were available for capsular typing and antibiotic susceptibility testing. The median age of the children from whom S. pneumoniae was isolated was 2.9 years (25% interquartile ratio [IR], 1.3 years; 75% IR, 4.5 years), and the ratio of males to females was 1.3:1. The distribution of the serotypes in the different age groups and the percentage of isolates nonsusceptible to penicillin are listed in Table 1. Eighty-two percent of the isolates were typeable, and the most common serotypes/serogroups were 6, 19, 23F, 14, 15, and 18. The potential proportions of serotype coverage by the 7-, 9-, and 11-valent vaccines were 72.3%, 72.4%, and 73.4%, respectively. If serogroups were included, the rate of PCV7 coverage increased to 74.4%, while the rates of 9- and 11-valent vaccine coverage increased to 74.6 and 75.7%, respectively.
TABLE 1.
Serotype | No. (%) of isolates from children in the following age (yr) groups:
|
No. of PNSP isolates (% S. pneumoniae) | |||||
---|---|---|---|---|---|---|---|
<2 | 2-3 | 3-4 | 4-5 | ≥5-15 | Total | ||
6B | 36 | 31 | 24 | 16 | 20 | 127 (24) | 103 (20) |
19F | 29 | 24 | 20 | 8 | 20 | 101 (19) | 81 (16) |
23F | 17 | 14 | 18 | 4 | 18 | 71 (14) | 50 (10) |
14 | 10 | 14 | 17 | 6 | 18 | 65 (13) | 56 (11) |
15 | 4 | 1 | 2 | 3 | 4 | 14 (3) | 1 |
18C | 3 | 3 | 1 | 1 | 2 | 10 (2) | 0 |
11 | 4 | 1 | 1 | 0 | 1 | 7 | 0 |
Non-19F | 2 | 1 | 1 | 0 | 2 | 6 | 2 |
3 | 3 | 0 | 1 | 1 | 0 | 5 | 0 |
33 | 5 | 0 | 0 | 0 | 0 | 5 | 0 |
10 | 2 | 0 | 0 | 0 | 1 | 3 | 0 |
Non-6B (6A) | 1 | 0 | 0 | 0 | 1 | 2 | 0 |
Non-23F | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
22 | 2 | 0 | 0 | 0 | 0 | 2 | 0 |
18B | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
4 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
9L | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Nontypeable | 46 | 7 | 8 | 9 | 25 | 95 (18) | 44 (8) |
Subtotal | 167 | 96 | 94 | 48 | 114 | 519 (100) | 337 (64.9) |
A total of 519 isolates were tested. PNSP isolates were those for which the penicillin MIC was ≥0.12 μg/ml.
The antibiotic susceptibilities of the 519 S. pneumoniae isolates are listed in Table 2. The prevalence of PNSP was 64.9%, while the prevalence of cefotaxime nonsusceptibility (MIC ≥ 1.0 μg/ml) among the S. pneumoniae isolates was 37.2%. High rates of nonsusceptibility to erythromycin (75.7%) and tetracycline (61.8%) were obtained. No resistance to respiratory fluoroquinolones was detected, except that 2.3% of the S. pneumoniae isolates had ciprofloxacin MICs of 4.0 μg/ml, suggesting that first-step mutations at the quinolone resistance-determining region may already have been present in some isolates. All isolates were susceptible to linezolid. The highest penicillin MIC remained at 4.0 μg/ml, but high-level cefotaxime resistance (MIC > 4 μg/ml) was identified. A previous report described two fatal cases of pneumococcal bacteremia in children, one of whom also had meningitis, that were caused by strains with cefotaxime MICs of 4 μg/ml (18).
TABLE 2.
Antibiotic | MIC range (μg/ml) | No. of isolates
|
% of isolates nonsusceptibleb | ||
---|---|---|---|---|---|
Sensitive | Intermediate | Resistant | |||
Penicillin | 0.008-4.0 | 182 | 212 | 125 | 64.9 |
Cefotaxime (nonmeningitis) | 0.015-≥4.0 | 451 | 41 | 27 | 13.0 |
Cefotaxime (meningitis) | 0.015-≥4.0 | 326 | 125 | 68 | 37.2 |
Erythromycin | 0.03->64.0 | 126 | 24 | 369 | 75.7 |
Lincomycin | 0.25->32.0 | 225 | 43.4 | ||
Tetracycline | 0.06->16.0 | 198 | 8 | 313 | 61.8 |
Chloramphenicol | 1.0-32 | 427 | 92 | 17.7 | |
Linezolid | 0.12-2.0 | 519 | —c | ||
Ciprofloxacin | 0.25-4.0 | 12d | 2.3 | ||
Levofloxacin | 0.25-2.0 | 519 | 0 | 0 | 0 |
Gatifloxacin | 0.06-0.5 | 519 | 0 | 0 | 0 |
Moxifloxacin | 0.03-0.25 | 519 | 0 | 0 | 0 |
A total of 519 isolates were tested.
Nonsusceptible isolates were those that were intermediate and resistant.
No CLSI breakpoint was available.
MIC ≥ 4.0 μg/ml.
The antibiotic resistance profiles and the serotypes of these S. pneumoniae isolates reflect strains which may be associated both with carriage and with acute respiratory illness. Ho et al. (7) compared both invasive and nasopharyngeal carriage isolates from children and did not find significant differences in terms of resistance rates or serotypes. Our potential seven-valent vaccine coverage rate fell between that based on invasive isolates (89.7%) and that based on nasopharyngeal carriage (66.1%) (7). Previous data concerning the serotypes from the group <2 years of age were very limited and were based on 33 invasive isolates saved over a 6-year period (2, 7). However, a lower rate of carriage based on nasopharyngeal isolates would be expected and was shown in a study from Taiwan (12). The application of DNA amplification by sequential multiplex PCR of the specific capsular genes (14) may further identify the serogroups or serotypes presently nontypeable with the Pneumotest antisera. Our previous findings indicated that PNSP was significantly associated with children, particularly those 2 to 10 years of age (8). A rapid rise in the incidence of PNSP was seen in Hong Kong beginning in the early 1990s as a result of the spread of multidrug-resistant clones of Spain23F-1 and Spain6B-2 (9-11). Based on recent outcomes on the use of PCV7 in populations with a high prevalence of PNSP infection or carriage, PNSP is likely to remain prevalent until the vaccine can be introduced to effectively reduce the incidence of invasive pneumococcal infections caused by these resistant strains.
The pneumococcal population is undergoing strong evolutionary pressure to change as the conjugate vaccine is used more extensively in different parts of the world. This study emphasizes the need for surveillance of the antibiotic resistance rates and serotypes of S. pneumoniae isolates with the changing scene as vaccination programs and antibiotic stewardships are being introduced.
Acknowledgments
The work described in this paper was supported by a grant from Wyeth (Hong Kong) Limited for the study on Hospital Surveillance of Childhood Respiratory Infections in Hong Kong.
Footnotes
Published ahead of print on 4 April 2007.
REFERENCES
- 1.Black, S., H. Shinefield, B. Fireman, M. A. Bruce, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. H. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards, and The Northern California Kaiser Permenente Vaccine Study Center Group. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195. [DOI] [PubMed] [Google Scholar]
- 2.Chiu, S. S., P. L. Ho, F. K. Chow, K. Y. Yuen, and Y. L. Lau. 2001. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob. Agents Chemother. 45:2765-2770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, fifteenth informational supplement, 15th ed. M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
- 4.Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, G. Siber, and P. H. Makelä for The Finnish Otitis Media Study Group. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409. [DOI] [PubMed] [Google Scholar]
- 5.Reference deleted.
- 6.Reference deleted.
- 7.Ho, P. L., K. F. Lam, F. K. H. Chow, Y. L. Lau, S. S. Y. Wong, S. L. E. Cheng, and S. S. Chiu. 2004. Serotype distribution and antimicrobial resistance patterns of nasopharyngeal and invasive Streptococcus pneumoniae isolates in Hong Kong children. Vaccine 22:3334-3339. [DOI] [PubMed] [Google Scholar]
- 8.Ip, M., D. J. Lyon, and A. F. Cheng. 2001. Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong. Chemotherapy 47:110-116. [DOI] [PubMed] [Google Scholar]
- 9.Ip, M., D. J. Lyon, R. W. H. Yung, C. Chan, and A. F. B. Cheng. 1999. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. J. Clin. Microbiol. 37:2834-2839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ip, M., D. J. Lyon, R. W. H. Yung, L. Tsang, and A. F. B. Cheng. 2002. Introduction of new clones of penicillin-nonsusceptible Streptococcus pneumoniae into Hong Kong. J. Clin. Microbiol. 40:1522-1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ip, M., D. J. Lyon, R. W. H. Yung, C. Chan, and A. F. B. Cheng. 2001. Macrolide resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 45:1578-1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lauderdale, T. L., M. M. Wagener, H. M. Lin, I. F. Huang, W. Y. Lee, K. S. Hseih, J. F. Lai, and C. C. Chiou. 2006. Serotype and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from Taiwanese children: comparison of nasopharyngeal and clinical isolates. Diagn. Microbiol. Infect. Dis. 56:421-426. [DOI] [PubMed] [Google Scholar]
- 13.O'Halloran, D. M., and M. T. Cafferkey. 2005. Multiplex PCR for identification of seven Streptococcus pneumoniae serotypes targeted by a seven-valent conjugate vaccine J. Clin. Microbiol. 43:3487-3490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Pai, R., R. E. Gertz, and B. Beall. 2006. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J. Clin. Microbiol. 44:124-131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Stephens, D. S., S. M. Zughaier, C. G. Whitney, W. S. Baughman, L. Barker, K. Gay, D. Jackson, W. A. Orenstein, K. Arnold, A. Schuchat, M. M. Farley, and the Georgia Emerging Infections Program. 2005. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365:855-863. [DOI] [PubMed] [Google Scholar]
- 16.Temime, L., D. Guillemot, and P. Y. Hall. 2004. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance. Antimicrob. Agents Chemother. 48:2206-2213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Whitney, C. G., M. M. Farley, J. Hadler, L H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pillshvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746. [DOI] [PubMed] [Google Scholar]
- 18.Wong, S. S., P. C. Woo, P. L. Ho, V. C. Cheng, and K. Y. Yuen. 1999. Emergence of Streptococcus pneumoniae with high-level resistance to cefotaxime in Hong Kong. Hong Kong Med. J. 5:406-409. [PubMed] [Google Scholar]